关于难控制高血压<\/u><\/b>?<\/u>
高血压是一种以血压持续升高为特征的医学疾病，影响全球约14亿人^{[6],[21],[22]<\/sup>。长期高血压可损伤血管及重要器官，增加心肌梗死、卒中、心衰和肾脏疾病等严重健康问题的风险^{[20],[21]<\/sup>。一项纳入近60,000名患者、中位随访时间9.7年的观察性研究显示，24小时动态收缩压每升高9.5 mmHg，全因死亡风险增加30%，心血管死亡风险增加41%^{[4]<\/sup>。研究还表明，夜间血压升高与更高的心血管风险相关^{[8],[11]<\/sup>，且高血压患者在清晨血压激增期间发生心肌梗死、卒中和死亡等心血管事件的风险更高^{[2],[3]<\/sup>。<\/p> \n}}}}}

难控制（未控制和难治性）高血压仍然是一项重大公共卫生挑战^{[23]<\/sup>。在美国，即便接受生活方式干预及多种药物治疗，约50%已接受治疗的高血压患者仍未能实现血压控制^{[7]<\/sup>。未控制高血压指接受两种及以上降压药物治疗后血压仍持续升高，而更严重的难治性高血压则指接受三种及以上药物治疗后血压仍无法控制^{[7],[21]<\/sup>。目前指南建议大多数高血压患者的血压控制目标为＜130\/80 mmHg ^{[21],[22]<\/sup>。<\/p> \n}}}}

醛固酮作为调控血压的关键激素，通过促进钠水潴留机制升高血压，是难控制高血压的重要致病因素^{[24],[25]<\/sup>。醛固酮水平升高，以及合并有肥胖、高盐摄入量以及各种遗传和继发性疾病等因素^{[26]<\/sup>，与血压控制不佳密切相关。若不及时治疗，高血压会显著增加心血管及肾脏相关并发症的风险^{[21],[22]<\/sup>。<\/p> \n}}}

Bax24 III期试验^{[16]<\/sup>是一项随机、双盲、安慰剂对照、平行组研究，旨在评估在难治性高血压受试者中，每天一次（QD）口服Baxdrostat 2mg相较安慰剂，降低动态收缩压的疗效，以及安全性和耐受性。试验共纳入218名患者，按1:1随机分配，在12周的双盲期内每日一次接受Baxdrostat 2mg或安慰剂治疗。主要疗效终点为第12周时24小时动态平均收缩压较基线的变化。<\/p> \n}

其他次要终点包括评估在第12周时相较安慰剂，Baxdrostat在以下各方面的效果：夜间动态平均收缩压较基线的变化、日间动态平均收缩压较基线的变化、坐位收缩压较基线的变化、24小时动态平均收缩压降至130mmHg以下的受试者人数、24小时动态舒张压较基线的变化、夜间动态平均舒张压较基线的变化、日间动态平均舒张压较基线的变化、坐位舒张压较基线的变化，以及达到夜间收缩压降幅超过10%的受试者人数。在12周的治疗期和2周安全随访期内评估不良事件的发生。<\/p> \n

Baxdrostat是一种有望成为首创新药的高选择性、强效口服小分子药物，可抑制醛固酮合酶^{[12]<\/sup>，该酶由 CYP11B2 基因编码，负责肾上腺中醛固酮的合成^{[24]<\/sup>。临床研究表明，Baxdrostat 可在较大剂量范围内显著降低醛固酮水平且不影响皮质醇水平^{[13],[27]<\/sup>。目前，该药正在作为单药疗法针对高血压^{[13]-[16]<\/sup>和原发性醛固酮增多症^{[17]<\/sup>开展临床试验评估，以及与达格列净联合用于治疗慢性肾脏病合并高血压^{[18],[19]<\/sup>，及高危患者心力衰竭的预防^{[20]<\/sup>。<\/p> \n}}}}}}}

阿斯利康于2023年2月通过收购 CinCor Pharma 公司获得 Baxdrostat。^{[28]<\/sup><\/p> \n}

关于阿斯利康在心血管、肾脏及代谢治疗领域<\/u><\/b><\/p> \n

心血管、肾脏及代谢始终是阿斯利康从全球到中国深耕的重要治疗领域和增长引擎。阿斯利康通过科学研究，深入了解心脏、肾脏和胰腺之间的潜在联系，积极投身于创新药物的研发，来有效保护器官，减缓甚至阻止疾病进展，最终让再生疗法成为可能。阿斯利康致力于通过更好地理解心血管、肾脏及代谢疾病之间的相互关联，从疾病的驱动机制着手，为患者提供更早、更有效地检测、诊断和治疗方案，从而改善和挽救数百万人的生命。<\/p> \n

阿斯利康（LSE\/STO\/Nasdaq: AZN）是一家科学至上的全球生物制药企业，专注于研发、生产及营销处方类药品，重点关注肿瘤、罕见病以及包括心血管肾脏及代谢、呼吸及免疫在内的生物制药等领域。阿斯利康全球总部位于英国剑桥，业务遍布超过125个国家，创新药物惠及全球数百万患者。更多信息，请访问www.astrazeneca.com。<\/p> \n

声明：<\/i>本文涉及尚未在中国大陆获批的产品和适应症，阿斯利康不推荐任何未被批准的药品使用。<\/i><\/p> \n

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
[1] Bax24 AHA presentation\/Publication<\/span><\/p> <\/td> \n <\/tr> \n
[2] Renna NF, et al. Morning blood pressure surge as a predictor of cardiovascular events in
patients with hypertension. Blood Press Monit<\/i>. 2023;28(3):149-157 <\/span><\/p> <\/td> \n <\/tr> \n
[3] Kario K et al. Morning hypertension: the strongest independent risk factor for stroke in elderly
hypertensive patients. Hypertens Res<\/i>. 2006;29(8):581-7. <\/span><\/p> <\/td> \n <\/tr> \n
[4] Staplin N, et al. Relationship between clinic and ambulatory blood pressure and mortality: an
observational cohort study in 59?124 patients. Lancet. 2023;401(10393):2041-2050.?<\/span><\/p> <\/td> \n <\/tr> \n
[5] Flack JM, et al. Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.
N Engl J Med<\/i>. 2025. Aug 30:10.1056\/NEJMoa2507109.?doi: 10.1056\/NEJMoa2507109. <\/span><\/p> <\/td> \n <\/tr> \n
[6] World Health Organization. Global report on hypertension 2025: high stakes: turning evidence
into action. 2025. https:\/\/iris.who.int\/handle\/10665\/382841<\/a>. Accessed September 2025. <\/span><\/p> <\/td> \n <\/tr> \n
[7] Carey RM, et al. Prevalence of Apparent Treatment-Resistant Hypertension in the United
States. Hypertension<\/i>. 2019;73(2):424-431.<\/span><\/p> <\/td> \n <\/tr> \n
[8] Narita K, et al. Nighttime Home Blood Pressure Is Associated With the Cardiovascular
Disease Events Risk in Treatment-Resistant Hypertension. Hypertension<\/i>. 2022;79(2):e18-e20 <\/span><\/p> <\/td> \n <\/tr> \n
[9] Kario K, et al. Nighttime Blood Pressure Phenotype and Cardiovascular Prognosis.
Circulation<\/i>. 2020;142(19):1810-1820<\/span><\/p> <\/td> \n <\/tr> \n
[10] Williams B, et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension: The
Task Force for the management of arterial hypertension of the European Society of
Cardiology (ESC) and the European Society of Hypertension (ESH). European Heart Journal.<\/i>
2018;39(33):3021-3104. <\/span><\/p> <\/td> \n <\/tr> \n
[11] Niiranen TJ, Mäki J, Puukka P, Karanko H, Jula AM. Office, home, and ambulatory blood
pressures as predictors of cardiovascular risk. Hypertension. 2014 Aug;64(2):281-6. <\/span><\/p> <\/td> \n <\/tr> \n
[12] Bogman K, et al. Preclinical and early clinical profile of a highly selective and potent oral
inhibitor of aldosterone synthase (CYP11B2). Hypertension.<\/i> 2017;69(1):189-196.<\/span><\/p> <\/td> \n <\/tr> \n
[13] Freeman MW, et al. Results from a phase 1, randomized, double-blind, multiple ascending
dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity
of the aldosterone synthase inhibitor baxdrostat in healthy volunteers. Hypertens Res.<\/i>
2023;46(1):108-118.<\/span><\/p> <\/td> \n <\/tr> \n
[14] ClinicalTrials.gov.A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants
With Uncontrolled Hypertension on Two or More Medications Including Participants With
Resistant Hypertension (BaxHTN). Available at: https:\/\/clinicaltrials.gov\/study\/NCT06034743<\/a>.
Accessed October 2025. <\/span><\/p> <\/td> \n <\/tr> \n
[15] ClinicalTrials.gov. A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants
With Uncontrolled Hypertension on Two or More Medications Including Participants With
Resistant Hypertension (BaxAsia). Available at: https:\/\/clinicaltrials.gov\/study\/NCT06344104<\/a>.
Accessed October 2025. <\/span><\/p> <\/td> \n <\/tr> \n
[16] ClinicalTrials.gov. A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood
Pressure in Participants With Resistant Hypertension (Bax24). Available
at: https:\/\/clinicaltrials.gov\/study\/NCT06168409<\/a>. Accessed October 2025. <\/span><\/p> <\/td> \n <\/tr> \n
[17] ClinicalTrials.gov. A Study to Assess Efficacy and Safety of Baxdrostat in Participants With
Primary Aldosteronism (BaxPA). Available at: https:\/\/clinicaltrials.gov\/study\/NCT07007793<\/a>.
Accessed October 2025. <\/span><\/p> <\/td> \n <\/tr> \n
[18] ClinicalTrials.gov. A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in
Combination With Dapagliflozin on CKD Progression in Participants With CKD and High
Blood Pressure. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06268873<\/a>.
Accessed October 2025. <\/span><\/p> <\/td> \n <\/tr> \n
[19] ClinicalTrials.gov. A Phase III Renal Outcomes and Cardiovascular Mortality Study to
Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in
Participants With Chronic Kidney Disease and High Blood Pressure (BaxDuo-Pacific).
Available at: https:\/\/clinicaltrials.gov\/study\/NCT06677060<\/a>. Accessed October 2025. <\/span><\/p> <\/td> \n <\/tr> \n
[20] ClinicalTrials.gov. Phase III Study Investigating Heart Failure and Cardiovascular Death With
Baxdrostat in Combination With Dapagliflozin (Prevent-HF). Available
at: https:\/\/clinicaltrials.gov\/study\/NCT06677060<\/a>. Accessed October 2025. <\/span><\/p> <\/td> \n <\/tr> \n
[21] McEvoy JW, et al. 2024 ESC Guidelines for the management of elevated blood pressure and
hypertension. Eur Heart J.<\/i> 2024;45(38):3912-4018.<\/span><\/p> <\/td> \n <\/tr> \n
[22] Jones DW, et al. 2025
AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM Guideline for
the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A
Report of the American College of Cardiology\/American Heart Association Joint Committee
on Clinical Practice Guidelines. Circulation<\/i> 2025;152:e114–e218.<\/span><\/p> <\/td> \n <\/tr> \n
[23] NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence
and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201
population-representative studies with 104 million participants. Lancet<\/i>. 2021;398(10304):957-980.<\/span><\/p> <\/td> \n <\/tr> \n
[24] Cannavo A, et al. Aldosterone and mineralocorticoid receptor system in cardiovascular
physiology and pathophysiology. Oxid Med Cell Longev<\/i>. 2018;2018:1204598.<\/span><\/p> <\/td> \n <\/tr> \n
[25] Inoue K, et al. Serum aldosterone concentration, blood pressure, and coronary artery calcium:
The multi-ethnic study of atherosclerosis. Hypertension<\/i>. 2020;76(1):113-120.<\/span><\/p> <\/td> \n <\/tr> \n
[26] van Oort S, et al. Association of cardiovascular risk factors and lifestyle behaviors with
hypertension: a mendelian randomization study. Hypertension. 2020;76(6):1971-1979. <\/span><\/p> <\/td> \n <\/tr> \n
[27] Freeman MW, et al. Phase 2 trial of baxdrostat for treatment-resistant hypertension. N Engl J<\/i>
Med<\/i>. 2023;388(5):395-405.<\/span><\/p> <\/td> \n <\/tr> \n
[28] AstraZeneca 2023. Acquisition of CinCor Pharma complete.
https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2023\/astrazeneca-acquires-
cincor-for-cardiorenal-asset.html<\/a>. Accessed October 2025. <\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n
<\/p> \n
\n<\/div>"]; $("#dvExtra").html(content_array[0]);})();